Vitestro Starts Largest-scale Clinical Trial Globally for its Autonomous Blood Drawing Device, with Enrolment of First Patients in A.D.O.P.T.
Vitestro expects to obtain CE marking by the end of 2024. The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Optimization and Performance Tests for Blood Testing) Trial at study site Result Laboratorium in the Albert Schweitzer Hospital. Investigational partners, in addition to Result Laboratorium - Albert Schweitzer Hospital, are St. Antonius, OLVG Lab and Amsterdam UMC.